镇脑宁胶囊联合氯沙坦钾治疗原发性高血压的临床研究  

Clinical study on Zhennaoning Capsules combined with losartan potassium in treatment of essential hypertension

作　　者：薛延辉 李春霞 尚敬[2] XUE Yan-hui;LI Chun-xia;SHANG Jing(Department of Endocrine,Pingdingshan Xinhua District People’s Hospital,Pingdingshan 467000,China;Department of Endocrine,Henan Provincial People’s Hospital,Zhengzhou 450000,China)

机构地区：[1]平顶山市新华区人民医院内分泌科,河南平顶山467000 [2]河南省人民医院内分泌科,河南郑州450000

出　　处：《现代药物与临床》2021年第7期1467-1470,共4页Drugs & Clinic

摘　　要：目的探讨镇脑宁胶囊联合氯沙坦钾片治疗原发性高血压的临床效果。方法选取2017年8月—2020年8月于平顶山市新华区人民医院诊疗的106例原发性高血压患者,根据入院顺序分成对照组和治疗组,每组分别53例。对照组口服氯沙坦钾片,50 mg/次,1次/d;治疗组患者在对照组基础上口服镇脑宁胶囊,1.2 g/次,3次/d。两组患者均连续治疗8周。观察两组患者临床疗效,比较治疗前后两组患者24 h平均收缩压和平均舒张压,及血清N-端脑利钠肽前体(NT-proBNP)、血管性血友病因子(vWF)水平和尿微量白蛋白水平。结果治疗后,治疗组总有效率为96.23%,明显高于对照组的84.91%(P<0.05);治疗后,两组患者24 h平均收缩压和24 h平均舒张压均显著下降(P<0.05),且治疗组明显低于对照组(P<0.05);治疗后,两组患者血清NT-proBNP、v WF水平和尿微量白蛋白水平均显著下降(P<0.05),且治疗组明显低于对照组(P<0.05)。结论镇脑宁胶囊联合氯沙坦钾片治疗原发性高血压疗效显著,能够有效控制患者动态血压水平,降低血清学指标水平,安全性高,具有一定临床推广应用价值。Objective To explore the clinical effect of Zhennaoning Capsules combined with losartan potassium in treatment of essential hypertension. Methods Patients(106 cases) with essential hypertension in Pingdingshan Xinhua District People’s Hospital from August 2017 to August 2020 were divided into control and treatment groups according to the order of admission, and each group had 53 cases. Patients in the control group were po administered with Losartan Potassium Tablets, 50 mg/time, once daily. Patients in the treatment group were po administered with Zhennaoning Capsules on the basis of the control group, 1.2 g/time, three times daily.Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the 24 h mean systolic blood pressure and mean diastolic blood pressure, the serum NT-proBNP, vWF and urinary microalbumin levels in two groups before and after treatment were compared. Results After treatment, the total clinical effective rate of the treatment group was 96.23%, which was significantly higher than 84.91% of the control group(P < 0.05). After treatment, 24 h average systolic blood pressure and 24 h average diastolic blood pressure were significantly decreased in two groups(P < 0.05), and which in the treatment group was significantly lower than those in the control group(P < 0.05). After treatment, the levels of serum NT-proBNP, vWF and urinary microalbumin in two groups were significantly decreased(P < 0.05), and which in the treatment group were significantly lower than those in the control group(P < 0.05). Conclusion Zhennaoning Capsules combined with losartan potassium has significant curative effect in treatment of essential hypertension, can effectively control the level of ambulatory blood pressure and reduce the level of serological indexes with high safety, which has a certain clinical application value.

关 键 词：镇脑宁胶囊 氯沙坦钾片 原发性高血压 尿微量白蛋白 N-端脑利钠肽前体 血管性血友病因子 

分 类 号：R971[医药卫生—药品]